← 홈

HER2+ 유방암

466개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 466개
ADCSHOTFDACuratedFDABiologicDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 79.7%임상시험 224상태 APPROVED
ADCSHOTFDACuratedFDABiologicRocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 80%임상시험 164상태 APPROVED
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 50%임상시험 153상태 ACTIVE
ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5
효능 ORR 79%임상시험 44상태 RECRUITING
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
AntibodyAHotstaleRocheDM1 via butelase-1 with ABD…Phase 3

trastuzumab (Herceptin)

Breast Cancer · Healthy

#Healthy#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 1044상태 ACTIVE
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 431상태 ACTIVE
ADCAHotBiologicImmunityBio, Inc.sPhase 3

Nab-paclitaxel (Nab-paclitaxel)

Triple Negative Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 69.1%임상시험 243상태 RECRUITING
AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 224상태 DISCONTINUED
ADCAHotBiologicCellerant TherapeuticsVedotin Therapy]Phase 3

Filgrastim (Filgrastim)

Male Breast Cancer; Stage II Breast Cancer · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88%임상시험 170상태 RECRUITING
AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 134상태 RECRUITING
ADCAHotBiologicNCIC Clinical Trials Groupvedotin, 120 mg intr…Phase 3

Epirubicin (Epirubicin)

Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88.6%임상시험 133상태 RECRUITING
AntibodyBHotInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 4.5%임상시험 123상태 RECRUITING
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 80%임상시험 119상태 RECRUITING
AntibodyBHotBiologicstaleRocheDM1 via butelase-1 with ABD…Phase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#인기#항체+5
효능 ORR 91.2%임상시험 113상태 RECRUITING
AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4
효능 ORR 76.7%임상시험 90상태 ACTIVE
ADCBBiologicstaleGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 87상태 RECRUITING
AntibodyCstaleRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING

1 / 24 페이지

← 이전다음 →